Non-Interventional Studies (NIS) Module 2: Practical Aspect

5/5
47
AdobeStock_240748797-1024x576

Duration :

2

hour(s)

Skill level:

Regulatory

Language:

English

Final exam:

Yes

Certificate of Completion:

Yes

CEU / CPD Accreditation:

Yes

Certification:

Gain a recognized and traceable certificate after completing the course : 

All our certificates are unique, authentic, CPD/CEU accredited, and FDA 21 CFR PART 11 compliant. Certificates validity can be checked online through our certificate online checker.

Description:

Non-Interventional studies are the class of research studies that do not interfere with the present line of therapy of the subject. These studies are great data sources for comparing the efficacy and safety of drug substances with others used to treat similar conditions at the post-marketing authorization stage. These studies may be conducted by sponsors willingly or as imposed upon them by regulatory agencies. This course goes deeper into the practical aspects of these studies teaching about the contents of reports and filing these reports with appropriate authorities and journals for accountability. Participants will also learn the importance of and relationship between PASS and Pharmacovigilance.

 

In this course, we provide a synthesis of the topic through an interactive online experience. This material was built by a team of Regulatory Affairs Experts with a Qualification from Northeastern University, Boston, piloted by a Senior Member able to articulate theory with practice.

 

 

Curriculum

 

Lesson 1: General Overview

 

Lesson 2: Post-authorization Safety Studies Non-Intervention Studies

 

  • European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCePP)
  • EU PAS Register
  • EMA Role

 

Lesson 3: Structure and Process on a Pass in NIS

 

  • Principles
  • Study Registration

 

Lesson 4: Study Protocol

 

  • Format and Content of the Study Protocol
  • Substantial Amendments to the Study Protocol

 

Lesson 5: Reporting of Pharmacovigilance Data to Competent Authorities

 

  • Data Relevant to The Risk-Benefit Balance of the Product
  • Reporting of Adverse Reactions/ Adverse Events
  • Study Reports

 

Lesson 6: Publication of Study Results

 

  • Submission of Manuscripts Accepted for Publication
  • Data Protection
  • Quality Systems, Audits, and Inspections
  • Impact on the Risk Management System

 

Lesson 7: Supervision of Non-Interventional Post-Authorization Safety Studies Conducted Under an Obligation

 

  • Roles and Responsibilities of the PRAC and the National Competent Authority
  • Roles and Responsibilities of the Agency

 

Lesson 8: Changes to the Marketing Authorization Following Results form a Non-Interventional Post-Authorization Safety Study

 

Lesson 9: Methods for Post-Authorization Safety Studies

 

Quiz

Author:

Capture-décran-2022-03-11-à-09.41.11
Dr. Faheem S. Khawaja
Dr. Faheem S. Khawaja (PharmD, MS) is an E-Learning content specialist, working as a Research Manager at Prime Foundation Pakistan, with 5 years of professional experience in healthcare and academia with a research interest in pharmaceutical nanotechnology and drug delivery systems. He is a highly capable and motivated Healthcare professional with superior analytical and problem-solving skills. Faheem possesses extensive knowledge of Pharmaceuticals and their regulatory bodies, database design, and medical informatics.

Reviews:

5/5
47
USD: United States (US) dollar ($)

$48.00 $60

Buy now
This course includes:
Full lifetime access
Updated content every month
Certificate of completion

GxP-Training Benefits

$48.00

$48.00

Frequently bought together

$48.00
$60

We might have this course but it's not displayed online. Please type your email and we will get back to you within 24h

No video yet for this course